Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV or recurrent non-small cell lung cancer that cannot be removed with surgery
- You have not had any previous cancer treatment for advanced or metastatic disease
- You have a tumor sample (fresh or within the last 5 months) that can be tested
- You are able to perform daily activities without much help (ECOG 0 or 1)
- You have at least one tumor that can be measured on scans
- You do not have a gene mutation that can be treated with a targeted therapy already available
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.